A couple of months after restructuring its R&D operations, Novo Nordisk has whipped up a $486 option deal to buy out Staten Biotechnology — if their lead drug comes through in clinical trials.
The main attraction at the Netherlands-based Staten is an anti-apoC3 antibody — dubbed STT-5058 — which has a shot at reducing triglycerides and remnant lipoproteins, well known targets in the high-risk cardio field.
The Danish biotech $NVO has divvied up its R&D group into 4 key operations, with their team in Oxford charged with taking the lead on cardio-metabolics. Novo will now lend assistance and R&D support to help push that development program along as it considers whether to follow up on the buyout option.
Marcus Schindler, Novo’s discovery chief, had this to say in a prepared statement:
Our partnership with Staten Biotechnology is a key step in executing our strategic priority to expand into cardiovascular diseases. Hypertriglyceridemia is a serious risk factor for cardiovascular disease, in particular often present in people with diabetes and obesity. Staten Biotechnology has developed STT-5058, a new promising concept validated by human genetics, for the treatment of hypertriglyceridemia. Combining Staten’s know-how on STT-5058, the scientific excellence of the company’s executive team and founders, with Novo Nordisk experience in drug development and commercialization, the project holds potential to make a real difference for people suffering from cardiovascular disease.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.Free Subscription